NCT05609552Completed
Biodistribution and Pharmacokinetics of Pretomanid in Tuberculosis Patients Using 18F-Pretomanid PET
Source: ClinicalTrials.gov · Last updated 12 Dec 2025
Brief summary (registry, in English)
This is an observational study that will examine the pretomanid pharmacokinetics (PK) in tuberculosis (TB) patients. Dynamic 18F-pretomanid PET/CT will be performed after intravenous injection of 18F-pretomanid to determine multi-compartment, noninvasive determination of pretomanid PK in TB patients.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 10 (actual)
- First submitted
- 1 Nov 2022
- Start date
- 22 May 2023
- Primary completion date
- 28 Oct 2025
- Lead sponsor
- Johns Hopkins University
- Diseases
- Tuberculosis
- NCT number
- NCT05609552
What you commit to
- Study type: Observational
- Participants enrolled: 10
- From 22 May 2023 to the primary completion date, 28 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any medical condition that in the judgment of the investigator would make the patient inappropriate for entry into this study
Other
- Inadequate venous access
Who the study is looking for
- Male or female ≥18 years of age at the time of consent and imaging
- Healthy subjects OR Subjects with confirmed tuberculosis OR high suspicion of active tuberculosis by treating physician.
- For TB patients: Imaging evidence of suspected tuberculosis infection involving the lung, and possible additional other sites of involvement.
- For TB patients: After TB diagnosis is confirmed, patients will be eligible to participate up to 6 weeks after starting TB treatment.
- Subject is willing to give written informed consent. Subject is willing and able to comply with the protocol for the duration of the study including undergoing scheduled visits and study procedures.
- Screening clinical laboratory values must be within normal limits or judged not clinically significant by the investigator.
- Women of child-bearing potential (WOCBP) must have a negative serum or urine pregnancy test within 24 hours prior to the radiotracer administration.
- Patients or their legal representatives must have the ability to read, understand and provide written informed consent for the initiation of any study-related procedures.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Johns Hopkins Medical Institutions Coordinator of this site? Confirm its status | Baltimore | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.